Inhaled budesonide

In April 2021, a trial ran by Principle concluded that early treatment with inhaled budesonide shortens recovery time by a median of three days in patients with COVID-19 who are at higher risk of more severe illness and are treated in the community. A common corticosteroid, budesonide is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings. Whilst this was the interim result of the trial, the action within the report is clear. "Prescribers are asked to: Consider prescribing inhaled budesonide (off-label, on a case-by-case basis) for symptomatic COVID-19 positive patients in line with the published Interim Position Statement using the usual routes, where supply allows." The inquiry should look into why the public has not been informed about this treatment.

Why the contribution is important

When a person contracts SARS Cov 2, he/she is advised to self isolate at home unless hospital treatment is required. The public has not been advised to contact their GP for COVID-19 treatment, therefore those eligible for this treatment have missed out on the opportunity. Whilst the above treatment is by no means a one-size-fits-all magic cure, it may help those people most at risk of developing serious disease.

by smskar on September 26, 2021 at 09:23PM

Current Rating

Average rating: 5.0
Based on: 1 vote